Mandeg, Chelly G.
HRN: 23-05-53 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/18/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
06/18/2023
06/25/2023
IVTT
45mg
OD
Newborn Affected By Maternal Factors (Maternal UTI)
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes